Hepatitis C Drugs: Who Wins and Who Loses?
August 16, 2017
It’s no secret that drug prices are a major problem in healthcare. Treatments for the hepatitis C virus (HCV) have a ripple effect from the individual to industrial scale. Manufacturers, the government, patients and practitioners all have something to gain—but even more